山西医科大学学报2026，Vol.57Issue(8)：885-892,8.DOI:10.13753/j.issn.1007-6611.2026.08.005
香豆素通过上调YBX1改善脊髓损伤后心肌细胞死亡
Coumarin attenuates spinal cord injury-induced cardiomyocyte death via up-regulation of YBX1
摘要
Abstract
Objective To investigate the effect and mechanism of coumarin in alleviating cardiomyocyte death induced by the serum of rats with spinal cord injury(SCI).Methods A rat model of SCI was established,and a sham-operated group was set as the control.H9c2 cardiomyocytes were cultured in vitro and divided into sham group,SCI group,YBX1 overexpression+SCI group,and SCI+cou-marin group.Cell viability was detected by CCK-8 assay.The mRNA and protein expression levels of YBX1 and IDE in myocardial tissues and H9c2 cells were measured by RT-qPCR and Western blot,respectively.The molecular docking between coumarin and YBX1 was performed using the SymMap database and the CB-dock2 platform.Results Compared with sham group,the hindlimb motor function score(BBB score)was significantly decreased in SCI group,and the mRNA and protein expression levels of YBX1 in myocardial tissues reduced(P<0.05).Compared with sham group,the cell viability of H9c2 cells significantly decreased in SCI group,and the mRNA and protein expression levels of YBX1 and IDE were significantly down-regulated(all P<0.05).Molecular docking results showed a theoretical binding potential between coumarin and YBX1.Compared with SCI group,the mRNA and protein expression levels of IDE in YBX1 overexpression+SCI group significantly increased(P<0.05).Compared with SCI group,the protein expression levels of YBX1 and IDE,and the cell viability were significantly increased in SCI+coumarin group(P<0.05).Conclusion Coumarin may increase the expression of IDE by up-regulating the expression of YBX1,thereby improving cardiomyocyte death induced by the serum of SCI rats.关键词
脊髓损伤/心肌细胞死亡/YBX1/IDE/香豆素Key words
spinal cord injury/cardiomyocyte death/YBX1/IDE/coumarin分类
医药卫生引用本文复制引用
张薇薇,王宏涛,杨兆飞,田栋梁,王丽,郝海虎..香豆素通过上调YBX1改善脊髓损伤后心肌细胞死亡[J].山西医科大学学报,2026,57(8):885-892,8.基金项目
山西省中医药管理局科研项目(2024ZYY2A020) （2024ZYY2A020）
